SGLT2抑制剂治疗2型糖尿病的研究进展

被引：14

作者：

李丽晶 ^{[1
]}

刘国平 ^{[2
]}

于磊 ^{[2
]}

机构：

[1] 内蒙古医科大学研究生学院

[2] 内蒙古自治区人民医院肾内科

来源：

中国中西医结合肾病杂志 | 2016年 / 17卷 / 01期

关键词：

抑制剂; 舒张压; 收缩压; 浮选药剂; 型糖尿病; SGLT2; 降糖药物; 低血糖; 患者体重; 胰岛素抵抗; 空腹血糖; β细胞;

D O I：

暂无

中图分类号：

R587.1 [糖尿病];

学科分类号：

1002 ; 100201 ;

摘要：

<正>糖尿病患病率逐年增加,预计在未来的25年内患病人数会达5.9亿,其中2型糖尿病（type2 diabetes mellitus,T2DM）在成年糖尿病患者中占90%95%,主要表现为高血糖、胰岛素分泌不足和胰岛素抵抗。血糖长时间增高,增加了患者大血管病变和微血管病变的危险性,前者主要包括冠心病,周围大血管粥样硬化和脑卒中,后者主要包括:糖尿病视网膜病变、糖尿

引用

页码：82 / 85

页数：4

共 29 条

[1] 糖尿病肾病流行病学研究进展 [J].

谢席胜 ;

艾娜 ;

王宝福 ;

夏梦迪 ;

樊均明 .

中国中西医结合肾病杂志, 2013, 14 (10) :937-940

[2]

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial[J] . Martin Ridderstr?le,Knut Robert Andersen,Cordula Zeller,Gabriel Kim,Hans J Woerle,Uli C Broedl.The Lancet Diabetes & Endocrinology . 2014 (9)

[3]

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes[J] . Rosenstock,Julio,Jelaska,Ante,Frappin,Guillaume,Salsali,Afshin,Kim,Gabriel,Woerle,Hans J,Broedl,Uli C.Diabetes Care . 2014 (7)

[4] Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) [J].

Weir, Matthew R. ;

Kline, Irina ;

Xie, John ;

Edwards, Robert ;

Usiskin, Keith .

CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (09) :1759-1768

[5]

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes[J] . David Polidori,Andrea Mari,Ele Ferrannini.Diabetologia . 2014 (5)

[6]

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor[J] . André J. Scheen.Clinical Pharmacokinetics . 2014 (3)

[7]

Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial[J] . C. S. Kovacs,V. Seshiah,R. Swallow,R. Jones,H. Rattunde,H. J. Woerle,U. C. Broedl.Diabetes Obes Metab . 2014 (2)

[8] Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients [J].

Ferrannini, Ele ;

Muscelli, Elza ;

Frascerra, Silvia ;

Baldi, Simona ;

Mari, Andrea ;

Heise, Tim ;

Broedl, Uli C. ;

Woerle, Hans-Juergen .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :499-508

[9] Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production [J].

Merovci, Aurora ;

Solis-Herrera, Carolina ;

Daniele, Giuseppe ;

Eldor, Roy ;

Fiorentino, Teresa Vanessa ;

Tripathy, Devjit ;

Xiong, Juan ;

Perez, Zandra ;

Norton, Luke ;

Abdul-Ghani, Muhammad A. ;

DeFronzo, Ralph A. .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :509-514

[10]

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial[J] . F. J. Lavalle-González,A. Januszewicz,J. Davidson,C. Tong,R. Qiu,W. Canovatchel,G. Meininger.Diabetologia . 2013 (12)

← 1 2 3 →